Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Breast 1

Conditions

Melanoma 10Carcinoma, Non-Small-Cell Lung 9Carcinoma, Renal Cell 8Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Colorectal Neoplasms 4Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasms 2Lymphoma 2Head and Neck Neoplasms 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1Solid Tumors 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

spartalizumab 1pazopanib 1Trabectedin 1Radiotherapy, Intensity-Modulated 1Polymerase Chain Reaction 1Neoadjuvant Therapy 1Gene Expression Profiling 1Doxorubicin 1Blotting, Western 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Sarcoma, Alveolar Soft Part × spartalizumab × Clear all
NCT02936102 2025-11-14

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Novartis

Phase 1 Terminated
154 enrolled
BreastSarcoma

Chordoma, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡